Skip to content

Ernexa Therapeutics Inc.

ERNA ERNAW

CIK 0000748592

← back to feed
Revenue (TTM)
$9.21M
−70.7% YoY Q1 May 2026
Net Income (TTM)
−$18.09M
+68.4% YoY Q1 May 2026
EPS Diluted (TTM)
−$65.47
+95.4% YoY Q1 May 2026
Gross Margin
4.5%
Q1 May 2026
Operating Margin
-139.2%
Q1 May 2026
Net Margin
-196.5%
Q1 May 2026
Free Cash Flow (TTM)
−$14.27M
Q1 May 2026
Cash
$4.32M
Q1 May 2026
Total Debt
$2.03M
Q1 May 2026
Shares Outstanding
1.17M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings